National Lupus Outreach and Clinical Trial Education Program

an increased risk for developing lupus. African Americans account for 43% of all lupus cases, but African American enrollment in lupus clinical trials stands at 14%. Without enrollment in clinical trials that reflect the patient population the drug is intended to treat, a drug may be less effective or not effective at treating the disease in a large number of patients. Increasing minority participation in lupus clinical trials is important for addressing lupus-related racial and ethnic health disparities. Recipients will be expected to sustain increased enrollment of racial and ethnic minorities in lupus-related clinical trials through outreach and education interventions, and public-private and community partnerships. Recipients also will assess the impact of project findings by implementing a process and outcomes evaluation for dissemination to diverse stakeholders.